Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pevifoscorvir sodium - Aligos Therapeutics

Next Previous
Drug Profile

Pevifoscorvir sodium - Aligos Therapeutics

Alternative Names: ALG-000184

Latest Information Update: 16 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aligos Therapeutics
  • Class Alkynes; Amides; Antivirals; Cyclic ethers; Fluorobenzenes; Hepatoprotectants; Ketones; Nitriles; Pyrroles; Small molecules
  • Mechanism of Action Capsid protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 13 Jul 2026 Aligos Therapeutics completes enrolment of patients in phase-II B-SUPREME clinical trials in Hepatitis B (Monotherapy, Treatment-naive) in US, Canada, China, Taiwan, New Zealand, Moldova, United Kingdom, Hong Kong, Bulgaria, France, Italy, Romania, Spain, UK and South Korea(PO) (NCT06963710)
  • 06 Jul 2026 Pevifoscorvir sodium receives Breakthrough Therapy status for Hepatitis B in China before July 2026
  • 27 May 2026 Pharmacodynamics data from the phase II B-SUPREME trial in Hepatitis B released by Aligos Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top